Biofrontera Inc.

0 products tracked · names used in filings: Biofrontera Inc.

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Mon 28 Sep 2026🇺🇸 PDUFA datecompany-announced

Ameluz: PDUFA target action date (superficial basal cell carcinoma (sBCC))

Biofrontera Inc. (BFRI); sNDA; status: set; "Recent Operational Highlights ● Announced FDA’s completion of its filing review and filing acceptance of the Company’s supplemental New Drug Application (sNDA) for Ameluz ® PDT for the treatment of superficial basal cell carcinoma (sBCC), with a PDUFA target action date of September 28, 2026."; filed 2026-05-14 · source

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.